셀리드 Stock: price and insider trades · South Korea
No insider purchase over the last 90 days. The latest, by 강창율, was filed 14 Jul 2026.
셀리드: what insiders have been doing
Every trade that managers of 셀리드 disclose to DART (FSS) is tracked on this page. The company sits in the Health Care sector. From 1 November 2025 to 1 November 2026, the disclosure feed for 셀리드 logged 10 filings by 2 insiders.
The flow runs one way only: 1 insider bought (8 purchases totalling €14k) and nobody sold on the market. No amount is published for 6 filings, which the totals therefore leave out. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. 강창율 filed the largest purchase, €7,650, on 23 April 2026, which represents 0.025% of the company's market value. On the buying side, the filings list 1 chief executive among the declarants.
Compared with its exchange (2,655 companies, median 7 filings), a count of 10 filings is above the norm. Since 2021, the database holds 17 purchases and 21 sales by insiders of the company.
The last purchase on record was published on 14 July 2026, which is 119 days ago. Filings reach the DART (FSS) feed a median of 7 days after the trade. That lag is the time during which only the insider knows about the trade.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and UCB. Source: insider filings from DART (FSS). Past trades are no guide to future returns.
Who traded when
BuySaleSince the insiders bought
- -39.5%Entry ₩3,110 · Close 30 Oct 2026 ₩1,882
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- 6,000 sharesShareKRXDART:20260714000028Canonical exit: 12 Oct 2026 (T+90)
- 7,000 sharesShareKRXDART:20260709000017Canonical exit: 7 Oct 2026 (T+90)
- 8,000 sharesShareKRXDART:20260701000070Canonical exit: 29 Sept 2026 (T+90)
- 6,000 sharesShareKRXDART:20260630000021Canonical exit: 28 Sept 2026 (T+90)
- 4,300 sharesShareKRXDART:20260520000029Canonical exit: 18 Aug 2026 (T+90)
- 3,597 shares@ ₩3,113.47010.021% mcap45.7% of flowShareKRXDART:20260506000113Canonical exit: 28 Jul 2026 (T+90)
- ●Executives0DART
- 4,000 shares@ ₩3,337.500.025% mcap54.3% of flowShareKRXDART:20260423000044Canonical exit: 16 Jul 2026 (T+90)
- ●Executives0DART
- 52,649 sharesKRXDART:20260227008297Canonical exit: 23 Sept 2025 (T+90)
- 432,406 sharesKRXDART:20250526000434
- 7,000 sharesShareKRXDART:20250526000430
- ●Executives0DART
- ●Executives0DART
- 83,541 sharesShareKRXDART:20250207000634
- 34,987 sharesKRXDART:20240906000611Canonical exit: 8 Nov 2024 (T+90)
- 1,683,277 sharesKRXDART:20240814003596
- ShareKRXDART:20240814003510Canonical exit: 8 Nov 2024 (T+90)
- ShareKRXDART:20240814003437Canonical exit: 12 Nov 2024 (T+90)
- ShareKRXDART:20240814003379Canonical exit: 8 Nov 2024 (T+90)
- 262,158 sharesKRXDART:20240802000349
- ShareKRXDART:20240802000338
- 744,245 sharesKRXDART:20240723000340Canonical exit: 14 Oct 2024 (T+90)
- ShareKRXDART:20240723000266Canonical exit: 8 Oct 2024 (T+90)
25 of 62 declarations
About 셀리드
셀리드 is a healthcare and pharmaceutical company listed on the XKRX market. It specializes in developing innovative solutions for disease treatment.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
